Longevity Health Holdings Announces Business Updates

Rhea-AI Summary

Longevity Health Holdings (NASDAQ: XAGE) announced several key business updates. The company has entered into a merger agreement with 20/20 BioLabs on April 11, 2025, with an S-4 prospectus filed on May 8. Q1 unaudited sales showed growth for both companies: XAGE reported $663,000 (+8% YoY) while 20/20 achieved $562,000 (+15% YoY).

The company completed a 1-for-30 reverse stock split on May 12, 2025. Both companies plan Q2 product launches: XAGE will introduce a medicated cleanser for medical professionals, while 20/20 will launch a blood inflammatory biomarker test. Additionally, 20/20 initiated a pilot program with Giant Food for their OneTest™ multi-cancer test at 9 stores in Maryland and Virginia. XAGE is exploring additional financing options for Q2 2025.

Positive

• Merger agreement executed with 20/20 BioLabs, expanding product portfolio and market reach
• Q1 sales growth: XAGE +8% YoY to $663,000; 20/20 +15% YoY to $562,000
• New product launches planned for Q2, including medicated cleanser and blood biomarker test
• Retail expansion through Giant Food pilot program for OneTest™ cancer screening

Negative

• 1-for-30 reverse stock split implemented, typically indicating share price concerns
• Need for additional financing in Q2 2025 suggests potential capital constraints
• Merger completion subject to conditions and regulatory approval

Insights

Financial Analyst

XAGE announces merger with 20/20 BioLabs, moderate sales growth, reverse split, and new product launches—strategic moves amid likely financial challenges.

Examining Longevity Health Holdings' (XAGE) recent business updates reveals a company actively restructuring while pursuing growth initiatives. The merger with 20/20 BioLabs appears strategically complementary, combining XAGE's regenerative bio-aesthetics with 20/20's diagnostic capabilities. This integration could create cross-selling opportunities across their respective customer bases (physicians/MedSpas and firefighters).

The Q1 sales figures, while showing growth, reflect relatively modest absolute revenue: $663,000 for XAGE (8% YoY growth) and $562,000 for 20/20 (15% YoY growth). The combined entity would have approximately $1.22 million in quarterly revenue—still indicating a small-scale operation with combined annualized revenue around $4.9 million.

The 1-for-30 reverse stock split completed on May 12 is particularly significant. Such dramatic consolidation typically signals serious underlying challenges, often implemented to maintain minimum share price requirements for continued Nasdaq listing or to make the stock more attractive to institutional investors. This aggressive ratio suggests the company was facing delisting risk due to sustained low share prices.

Their product pipeline expansion with a medicated cleanser and inflammatory biomarker test demonstrates attempts to enhance their market position through complementary offerings. The pilot with Giant Food for 20/20's OneTest™ multi-cancer test represents a potentially valuable retail distribution channel that could significantly expand their diagnostic reach beyond traditional medical settings.

The announcement that XAGE is "evaluating options" for additional financing in Q2 2025 indicates cash constraints and an imminent need for capital. Considering the reverse split and modest revenue base, this financing will likely be crucial for funding operations and merger integration.

Biotech Industry Specialist

XAGE's merger with 20/20 BioLabs combines complementary longevity technologies with novel retail distribution strategies for diagnostics.

The merger between Longevity Health Holdings and 20/20 BioLabs represents a strategic integration within the longevity and preventative healthcare space. By combining XAGE's regenerative bio-aesthetics portfolio with 20/20's diagnostic capabilities, the merged entity is positioning itself as a more comprehensive player across the longevity value chain.

From a product development perspective, the upcoming launches demonstrate a coordinated strategy to leverage their combined customer networks. XAGE's planned medicated cleanser targets both their existing physician/MedSpa channels and 20/20's firefighter customer base—a demographic frequently exposed to environmental toxins and skin damage. Similarly, 20/20's inflammatory biomarker test aligns with XAGE's anti-aging focus, as chronic inflammation is increasingly recognized as a key driver of biological aging processes.

The most technologically significant announcement is 20/20's retail initiative with Giant Food for their OneTest™ multi-cancer screening using capillary blood sampling. This represents an important shift toward consumer-accessible preventative diagnostics outside traditional clinical settings. The potential expansion to include food-related inflammatory biomarker testing further demonstrates an integrated approach to longevity through both detection and lifestyle intervention.

While both companies are showing revenue growth, the absolute figures remain modest for the biotech sector. The merger appears designed to achieve greater commercial scale and technological synergy rather than immediate financial transformation. The companies' complementary expertise in skin health, inflammation, and diagnostics creates a foundation for developing more integrated longevity solutions, though significant R&D investment will likely be required to fully capitalize on this potential.

The planned capital raise will be critical for executing their product development roadmap, particularly as they integrate operations and pursue retail distribution channels that typically require substantial marketing investment.

PITTSBURGH and GAITHERSBURG, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Longevity Health Holdings, Inc. (Nasdaq: XAGE), a company focused on extending human longevity and healthy aging through technologically innovative and clinically proven products in regenerative bio-aesthetics, diagnostics, and nutrition (“XAGE”, the “Company”, “we”, “our”, or “us”), today announced the following business updates:

1.   Merger Agreement entered with 20/20 BioLabs (“20/20”)

• Merger Agreement executed on April 11, 2025, pursuant to which 20/20 is expected to continue as a wholly owned subsidiary of XAGE following merger closing subject to the satisfaction of the conditions set forth in the Merger Agreement.
• S-4 prospectus filed with the Securities and Exchange Commission (SEC) on May 8, 2025.
  

2.   Unaudited Q1 sales

• XAGE: approximately $663,000 on a full quarter pro forma basis, an increase of 8% over the same period last year.
• 20/20: approximately $562,000, an increase of 15% over the same period last year.
  

3.   Reverse Stock Split

• Completed a 1 for 30 reverse stock split of XAGE’s common stock on May 12, 2025.
• Stock began trading at split adjusted price on May 14, 2025.
  

4.   Expected Q2 New Product Launches

• XAGE: expects to launch a medicated cleanser for use in Physicians’ offices and MedSpas. This cleanser will also be marketed to 20/20’s customer base which consists predominantly of firefighters.
• 20/20: expects to launch a new lab test that measures inflammatory biomarkers in the blood, a key contributor to premature aging and precursor to various skin and health disorders. This test will also be marketed to XAGE’s customer base of physicians and MedSpas.
• 20/20: announced an initiative with Giant Food at 9 stores in Maryland and Virginia to offer OneTest^TM, their multi-cancer test using capillary blood. Giant is also considering expanding the pilot to include a test that spots biomarkers linked to pro-inflammatory foods.

5.   Additional Financing

• XAGE is evaluating options and anticipates announcing a primary investment in Q2 2025.

About 20/20:
20/20 develops and commercializes innovative laboratory tests for the early detection and the proactive management of chronic disease risk. It offers a multi-cancer early detection blood test available in the U.S. accessible at home or at retail locations. This quarter, 20/20 also expects to introduce a new blood test for monitoring chronic inflammation which contributes to eight of the ten leading causes of death in America as well as skin disorders.

About XAGE:
Longevity Health Holdings is focused on longevity and healthy aging, encompassing the latest scientific advances in regenerative bio-aesthetics, diagnostics, and nutrition. Our products are aimed at helping people look and feel their best at any age. The Company currently offers two regenerative technologies for skin and hair health: the Carmell Secretome™ and Elevai Exosomes^TM. The Carmell Secretome™ is a powerful blend of growth factors, proteins, peptides and bio-lipids derived from allogeneic human platelets, the body’s principal healing and regenerative cell. Elevai Exosomes^TM are derived from human umbilical mesenchymal stem cells, which are known to contain a greater number of proteins than exosomes from non-stem cell sources.

Forward-Looking Statements:
This press release contains forward-looking statements that are based on beliefs, assumptions and information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology. However, not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements regarding preliminary unaudited sales for XAGE and 20/20; the launch and commercialization of new products by XAGE and 20/20; the structure, timing and completion of the proposed Merger; expectations regarding the ownership structure of the combined company; the anticipated timing of the Closing; the expected executive officers and directors of the combined company; expectations regarding the structure, timing and completion of a concurrent financing; the combined company’s expected post-Closing revenue and operational savings and synergies following the Merger; the future operations and products of the combined company. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, risks related to (i) the risk that the conditions to the Closing are not satisfied, including the failure to timely obtain stockholder approval for the transaction, if at all; (ii) uncertainties as to the timing of the consummation of the proposed Merger and the ability of each company to consummate the proposed Merger; (iii) risks related to XAGE’s ability to maintain its listing on the Nasdaq Capital Market and to manage its operating expenses and its expenses associated with the proposed Merger pending the Closing; (iv) risks related to the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the proposed Merger; (v) the risk that as a result of adjustments to the exchange ratio, each company’s stockholders could own more or less of the combined company than is currently anticipated; (vi) risks related to the market price of XAGE’s common stock relative to the value suggested by the exchange ratio; (vii) unexpected costs, charges or expenses resulting from the transaction; (viii) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed Merger; (ix) risks related to the inability of the combined company to obtain sufficient additional capital to continue to advance the commercialization, development and marketing of its products; (x) risks associated with the possible failure to realize certain anticipated benefits of the proposed Merger, including with respect to future financial and operating results; (xi) the risk that the concurrent financing is not consummated prior to the Closing; (xii) risks related to the diversion of management’s attention from our ongoing business; (xiii) the risk of unknown liabilities arising after the Merger; (xiv) the ability to recognize anticipated benefits from our commercial products, R&D pipeline, distribution agreements, changes in applicable laws or regulations; (xv) the possibility that we may be adversely affected by other economic, business, and/or competitive factors, and (xvi) other risks and uncertainties, those described under the header “Risk Factors” in the Annual Report on Form 10-K filed by XAGE with the U.S. Securities and Exchange Commission (the “SEC”) on March 31, 2025, and in our other reports filed with the SEC. Most of these factors are outside of XAGE’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. Except as required by law, we undertake no obligation to publicly update any forward-looking statement contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

No Offer or Solicitation
This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities nor a solicitation of any vote or approval with respect to the proposed transaction or otherwise. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U S. Securities Act of 1933, as amended, and otherwise in accordance with applicable law.

Additional Information and Where to Find It
This communication relates to the proposed Merger involving 20/20 and XAGE and may be deemed to be solicitation material in respect of the proposed Merger. In connection with the proposed Merger, XAGE has filed a registration statement on Form S-4 (the “Form S-4”) that contains a proxy statement (the “Proxy Statement”) and prospectus. This communication is not a substitute for the Form S-4, the Proxy Statement or for any other document that XAGE may file with the SEC and or send to XAGE’s stockholders in connection with the proposed Merger. BEFORE MAKING ANY VOTING DECISION, INVESTORS AND SECURITY HOLDERS OF XAGE ARE URGED TO READ THE FORM S-4, THE PROXY STATEMENT AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT XAGE, THE PROPOSED MERGER AND RELATED MATTERS.

Investors and security holders will be able to obtain free copies of the Form S-4, the Proxy Statement and other documents filed by XAGE with the SEC through the website maintained by the SEC at www.sec.gov. Copies of the documents filed by XAGE with the SEC will also be available free of charge on XAGE’s website at www.healthxage.com, or by contacting Bryan Cassaday at bcassaday@healthxage.com.

Participants in the Solicitation
XAGE, 20/20, and their respective directors and certain of their executive officers may be considered participants in the solicitation of proxies from XAGE’s stockholders with respect to the proposed Merger under the rules of the SEC. Information about the directors and executive officers of XAGE is set forth in its Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on March 31, 2025, subsequent Quarterly Reports on Form 10-Q and other documents that may be filed from time to time with the SEC. Additional information regarding the persons who may be deemed participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, will also be included in the Form S-4, the Proxy Statement and other relevant materials to be filed with the SEC when they become available. You may obtain free copies of these documents as described above.

Contact:
Bryan Cassaday
bcassaday@healthxage.com

FAQ

What is the merger deal between Longevity Health Holdings (XAGE) and 20/20 BioLabs?

Longevity Health Holdings signed a merger agreement with 20/20 BioLabs on April 11, 2025, where 20/20 will become a wholly owned subsidiary of XAGE. An S-4 prospectus was filed with the SEC on May 8, 2025.

What was XAGE's Q1 2025 sales performance?

XAGE reported unaudited Q1 2025 sales of approximately $663,000, representing an 8% increase compared to the same period last year.

What is the ratio of XAGE's reverse stock split in May 2025?

XAGE completed a 1-for-30 reverse stock split of its common stock on May 12, 2025, with trading at the adjusted price beginning on May 14, 2025.

What new products is Longevity Health Holdings (XAGE) launching in Q2 2025?

XAGE plans to launch a medicated cleanser for Physicians' offices and MedSpas, while 20/20 will introduce a blood inflammatory biomarker test and expand their OneTest™ multi-cancer screening program.

What is the Giant Food pilot program announced by XAGE and 20/20?

20/20 initiated a pilot program with Giant Food at 9 stores in Maryland and Virginia to offer OneTest™, their multi-cancer test using capillary blood, with potential expansion to include pro-inflammatory food biomarker testing.